Results 181 to 190 of about 32,980 (263)
Modeling immersion pathways in XR-based cultural heritage IP narrative experiences: an integrated approach based on TAM, experience economy, and grounded theory. [PDF]
Liu D, Jung J.
europepmc +1 more source
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi +2 more
wiley +1 more source
Participatory development of nursing curricula - a Global North-South partnership between Norwegian and Ethiopian universities. [PDF]
Abudayya A +9 more
europepmc +1 more source
openaire +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
How Digital Diaries Are Changing Communication and Recovery in the Intensive Care Unit and Beyond. [PDF]
Congdon J.
europepmc +1 more source
Student perspectives on AI‐supported formative assessment in pharmacology
Abstract Aims High‐quality feedback is crucial for helping medical students understand and apply core concepts of pharmacology, yet personalized feedback is resource‐intensive to produce. Artificial intelligence (AI) offers a potential solution, but little is known about students' perspectives on AI‐generated feedback.
Jon Andsnes Berg +6 more
wiley +1 more source
The health-promoting experiences of storytellers in group-based digital storytelling workshops: a meta-synthesis of qualitative studies. [PDF]
Dominguez Hernandez J +5 more
europepmc +1 more source
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source

